ALC - Alcon Inc.
SIX
->
Healthcare
->
Medical Instruments & Supplies
Geneva,
Switzerland
Type: Equity
ALC price evolution
ALC
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $2083 | $2032 | $2113 | $2096 |
| Inventory | $2322 | $2322 | $2270 | $2222 |
| Total current assets | $5647 | $5547 | $5200 | $5331 |
| Long term investments | ||||
| Property, plant & equipment | $4723 | $4488 | $4471 | $4457 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $29614 | $29369 | $29209 | $29291 |
| Current liabilities | ||||
| Accounts payable | $811 | $894 | $902 | $851 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $2480 | $2505 | $2406 | $2597 |
| Long term debt | $4929 | $4907 | $4935 | $4944 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $8990 | $9217 | $9270 | $9427 |
| Shareholders' equity | ||||
| Retained earnings | $20624 | $20169 | $19931 | $19840 |
| Other shareholder equity | $12 | $2 | $19 | $36 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $270 | $1557 | ||
| Short term investments | ||||
| Net receivables | $2083 | $1964 | $1786 | $1382 |
| Inventory | $2322 | $2109 | $1899 | $1644 |
| Total current assets | $5647 | $5193 | $5386 | $4987 |
| Long term investments | ||||
| Property, plant & equipment | $4723 | $4416 | $4083 | $3425 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $22613 | |||
| Total investments | ||||
| Total assets | $29614 | $29209 | $27999 | $27600 |
| Current liabilities | ||||
| Accounts payable | $811 | $861 | $903 | $876 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $2480 | $2782 | $2472 | $2258 |
| Long term debt | $4929 | $4900 | $4305 | $3949 |
| Total noncurrent liabilities | $6520 | |||
| Total debt | ||||
| Total liabilities | $8990 | $9532 | $8743 | $8778 |
| Shareholders' equity | ||||
| Retained earnings | $20624 | $19673 | $19356 | $18899 |
| Other shareholder equity | $12 | $17 | -$88 | $18802 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2352 | |||
| Cost of revenue | ||||
| Gross Profit | $1284 | |||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $1011 | |||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$259 | |||
| Interest expense | -$47 | |||
| Net income | ||||
| Net income | $427 | |||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $9455 | $8291 | $6833 | |
| Cost of revenue | ||||
| Gross Profit | $5254 | $4696 | $2940 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $4080 | $3766 | $3422 | |
| Operating income | -$482 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$142 | $42 | -$104 | |
| Interest expense | -$189 | -$147 | $124 | |
| Net income | ||||
| Net income | $974 | $376 | -$531 | |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$1094 | -$720 | -$568 | -$155 |
| Financing activities | ||||
| Dividends paid | -$116 | -$116 | -$116 | |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$211 | -$156 | -$166 | -$21 |
| Effect of exchange rate | $31 | $10 | $5 | |
| Change in cash and equivalents | $114 | $71 | -$319 | -$91 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Net income | -$531 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $823 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$1094 | -$1865 | -$1198 | -$572 |
| Financing activities | ||||
| Dividends paid | -$116 | -$100 | -$54 | |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$211 | -$8 | -$123 | $466 |
| Effect of exchange rate | $31 | $61 | -$6 | $18 |
| Change in cash and equivalents | $114 | -$595 | $18 | $735 |
News
Fundamentals
| Market cap | $35.91B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 493.30M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.28 |
| Quick ratio | 1.34 |